Karyotypic conversion by interferon as preparative treatment for autologous BMT in PH positive cml italian cooperative study group (ICSG) on chronic myeloid leukemia

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

This is an interim report of the Roferon A/ABMT protocol by ICSG on CML aimed at investigating the feasibility and potential of combining treatment with αIFN with ABMT in Ph+ CML. Of 675 Ph+ CML patients recruited between January 1989 and January 1991 by 44 Italian institutions, 398 were 55 or less years old and eligible for the protocol. Of 132 patients who completed IFN treatment 118 had evaluable karyotype; of these only 48 showed >25% Ph-metaphases and were eligible for BM harvest. In 24 patients BM was collected and 13 were submitted to ABMT. The major causes of drop out from the protocol were shift to allogeneic BMT, accelerated blastic phase, patient refusal and logistic problems. Data on hematologic reconstitution are presently available in 11 patients: Neutrophils were >0.5 × 109/1 in 23 days (median), (range 16-40 days); platelets reached 50 × 109/1 in 28 days (median), (range 25-100 days). One patient had a very delayed BM take and was rescued with autologous peripheral blood stem cells collected at diagnosis.

Original languageEnglish
Pages (from-to)277-280
Number of pages4
JournalLeukemia and Lymphoma
Volume11
Issue numbers1
DOIs
Publication statusPublished - 1993

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Interferons
Therapeutics
Metaphase
Karyotype
Neutrophils
Blood Platelets

Keywords

  • Autologous BMT
  • Interferon
  • Karyotypic conversion

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

@article{2b3aa6cdd33e42f6b225c21bf3439cee,
title = "Karyotypic conversion by interferon as preparative treatment for autologous BMT in PH positive cml italian cooperative study group (ICSG) on chronic myeloid leukemia",
abstract = "This is an interim report of the Roferon A/ABMT protocol by ICSG on CML aimed at investigating the feasibility and potential of combining treatment with αIFN with ABMT in Ph+ CML. Of 675 Ph+ CML patients recruited between January 1989 and January 1991 by 44 Italian institutions, 398 were 55 or less years old and eligible for the protocol. Of 132 patients who completed IFN treatment 118 had evaluable karyotype; of these only 48 showed >25{\%} Ph-metaphases and were eligible for BM harvest. In 24 patients BM was collected and 13 were submitted to ABMT. The major causes of drop out from the protocol were shift to allogeneic BMT, accelerated blastic phase, patient refusal and logistic problems. Data on hematologic reconstitution are presently available in 11 patients: Neutrophils were >0.5 × 109/1 in 23 days (median), (range 16-40 days); platelets reached 50 × 109/1 in 28 days (median), (range 25-100 days). One patient had a very delayed BM take and was rescued with autologous peripheral blood stem cells collected at diagnosis.",
keywords = "Autologous BMT, Interferon, Karyotypic conversion",
author = "Marco Gobbi",
year = "1993",
doi = "10.3109/10428199309047899",
language = "English",
volume = "11",
pages = "277--280",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "s1",

}

TY - JOUR

T1 - Karyotypic conversion by interferon as preparative treatment for autologous BMT in PH positive cml italian cooperative study group (ICSG) on chronic myeloid leukemia

AU - Gobbi, Marco

PY - 1993

Y1 - 1993

N2 - This is an interim report of the Roferon A/ABMT protocol by ICSG on CML aimed at investigating the feasibility and potential of combining treatment with αIFN with ABMT in Ph+ CML. Of 675 Ph+ CML patients recruited between January 1989 and January 1991 by 44 Italian institutions, 398 were 55 or less years old and eligible for the protocol. Of 132 patients who completed IFN treatment 118 had evaluable karyotype; of these only 48 showed >25% Ph-metaphases and were eligible for BM harvest. In 24 patients BM was collected and 13 were submitted to ABMT. The major causes of drop out from the protocol were shift to allogeneic BMT, accelerated blastic phase, patient refusal and logistic problems. Data on hematologic reconstitution are presently available in 11 patients: Neutrophils were >0.5 × 109/1 in 23 days (median), (range 16-40 days); platelets reached 50 × 109/1 in 28 days (median), (range 25-100 days). One patient had a very delayed BM take and was rescued with autologous peripheral blood stem cells collected at diagnosis.

AB - This is an interim report of the Roferon A/ABMT protocol by ICSG on CML aimed at investigating the feasibility and potential of combining treatment with αIFN with ABMT in Ph+ CML. Of 675 Ph+ CML patients recruited between January 1989 and January 1991 by 44 Italian institutions, 398 were 55 or less years old and eligible for the protocol. Of 132 patients who completed IFN treatment 118 had evaluable karyotype; of these only 48 showed >25% Ph-metaphases and were eligible for BM harvest. In 24 patients BM was collected and 13 were submitted to ABMT. The major causes of drop out from the protocol were shift to allogeneic BMT, accelerated blastic phase, patient refusal and logistic problems. Data on hematologic reconstitution are presently available in 11 patients: Neutrophils were >0.5 × 109/1 in 23 days (median), (range 16-40 days); platelets reached 50 × 109/1 in 28 days (median), (range 25-100 days). One patient had a very delayed BM take and was rescued with autologous peripheral blood stem cells collected at diagnosis.

KW - Autologous BMT

KW - Interferon

KW - Karyotypic conversion

UR - http://www.scopus.com/inward/record.url?scp=0027162046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027162046&partnerID=8YFLogxK

U2 - 10.3109/10428199309047899

DO - 10.3109/10428199309047899

M3 - Article

VL - 11

SP - 277

EP - 280

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - s1

ER -